Full Length Research Paper
References
|
Adamu AL, Gadanya MA, Abubakar IS (2017). High mortality among tuberculosis patients on treatment in Nigeria: a retrospective cohort study. BMC Infectious Diseases 170. Crossref |
||||
|
Albuquerque MF, Leitão CC, Campelo AR (2001) [Prognostic factors for pulmonary tuberculosis outcome in Recife, Pernambuco, Brazil]. Revista Panamericana de Salud Pública 9:368-374. Crossref |
||||
|
Anuwatnonthakate A, Limsomboon P, Nateniyom S (2008). Directly observed therapy and improved tuberculosis treatment outcomes in Thailand. PLoS One 3:e3089. Crossref |
||||
|
Baghaei P, Tabarsi P, Jabehdari S (2016). HIV and tuberculosis trends and survival of coinfection in a referral center in Tehran: A 12-year study. International Journal of Mycobacteriology 5(1):S16-S17. Crossref |
||||
|
Balabanova Y, Drobniewski F, Fedorin I (2006). The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation. Respiratory Research 7:44. Crossref |
||||
|
Bouti K, Aharmim M, Marc K (2013). Factors Influencing Sputum Conversion among Smear-Positive Pulmonary Tuberculosis Patients in Morocco. In: International Scholarly Research Notices. Crossref |
||||
|
Cui Z, Lin M, Nie S, Lan R (2017). Risk factors associated with Tuberculosis (TB) among people living with HIV/AIDS: A pair-matched case-control study in Guangxi, China. PLoS One 12:e0173976. Crossref |
||||
|
Darré T, Tchaou M, Sonhaye L (2015). Analyse d'une série de 44 cas de tuberculose péritonéale diagnostiqués au laboratoire d'anatomie pathologique du CHU Tokoin de Lomé (1993-2014). Bulletin de la Société De Pathologie Exotique 108:324-327. Crossref |
||||
| Dye C, Scheele S, Dolin P (1999). Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. https://www.ncbi.nlm.nih.gov/pubmed/?term=Consensus+statement.+Global+burden+of+tuberculosis%3A+estimated+incidence%2C+prevalence%2C+and+mortality+by+country. Accessed 13 Jul 2019 | ||||
|
Elmahalli AA, Abdel-Aziz BF (2007). Assessment of the implementation of DOTS strategy in two chest facilities in Alexandria, Egypt. Eastern Mediterranean Health Journal 13:1085-1097 Crossref |
||||
| European Centre for Disease Control and Prevention, Word Health Organization (2018). European Region SURVEILLANCE REPORT. Tuberculosis surveillance and monitoring in Europe 2017. P. 162 | ||||
|
Ferreira V, Brito C, Portela M (2011). DOTS in primary care units in the city of Rio de Janeiro, Southeastern Brazil. Revista de Saúde Pública 45:40-48. Crossref |
||||
|
He GX, Wang HY, Borgdorff MW (2011). Multidrug-resistant tuberculosis, People's Republic of China, 2007-2009. Emerging Infectious Diseases 17:1831-1838. Crossref |
||||
|
Heunis JC, Kigozi NG, Chikobvu P (2017). Risk factors for mortality in TB patients: a 10-year electronic record review in a South African province. BMC Public Health 17:38. Crossref |
||||
| Hounkpati A, Adjoh K, Agli K (2008). Miliaire tuberculeuse : caractéristiques cliniques, thérapeutiques, et évolutives au CHU de Lome-Togo. /data/revues/07618425/00220HS1/27_2/ | ||||
| Juan G, Lloret T, Perez C (2006). Directly observed treatment for tuberculosis in pharmacies compared with self-administered therapy in Spain. International Journal of Tuberculosis and Lung Disease 10:215-221 | ||||
|
Karo B, Hauer B, Hollo V (2015). Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002-2011. Eurosurveillance 20: Crossref |
||||
|
Kuaban C, Bame R, Mouangue L (2009). Non conversion of sputum smears in new smear positive pulmonary tuberculosis patients in Yaoundé, Cameroon. East African Medical Journal 86:219-225 Crossref |
||||
|
Lackey B, Seas C, Van der Stuyft P, Otero L (2015) Patient Characteristics Associated with Tuberculosis Treatment Default: A Cohort Study in a High-Incidence Area of Lima, Peru. PLoS One 10:e0128541. Crossref |
||||
|
Lee J, Lee BJ, Yoon HI (2012). Influence of previous tuberculosis treatment history on acid-fast bacilli smear and culture conversion. International Journal of Tuberculosis and Lung Disease 16:1344-1348. Crossref |
||||
| Lema NA, Mbelele PM, Majigo M (2016). Risk factors associated with multidrug resistant tuberculosis among patients referred to Kibong'oto Infectious Disease Hospital in northern Tanzania. Tanzania Journal of Health Research 18: | ||||
|
Mlotshwa M, Abraham N, Beery M (2016). Risk factors for tuberculosis smear non-conversion in Eden district, Western Cape, South Africa, 2007-2013: a retrospective cohort study. BMC Infectious Diseases 16:365. Crossref |
||||
| Muñoz-Sellart M, Cuevas LE, Tumato M (2010). Factors associated with poor tuberculosis treatment outcome in the Southern Region of Ethiopia. International Journal of Tuberculosis and Lung Disease 14:973-979 | ||||
|
Nagu TJ, Aboud S, Mwiru R (2017). Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy. International Journal of Infectious Diseases 56:39-44. Crossref |
||||
|
Nimagan S, Bopaka RG, Diallo MM (2015). [Predictive factors of TB treatment failure in Guinea Conakry]. Pan African Medical Journal 22:146. Crossref |
||||
|
Ntshanga SP, Rustomjee R, Mabaso MLH (2009). Evaluation of directly observed therapy for tuberculosis in KwaZulu-Natal, South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 103:571-574. Crossref |
||||
|
Pasipanodya JG, Gumbo T (2013). A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clinical Infectious Diseases 57:21-31. Crossref |
||||
|
Pefura-Yone EW, Balkissou AD, Poka-Mayap V (2017). Development and validation of a prognostic score during tuberculosis treatment. BMC Infectious Diseases 17:251. Crossref |
||||
|
Sawadogo B, Tint KS, Tshimanga M (2015). Risk factors for tuberculosis treatment failure among pulmonary tuberculosis patients in four health regions of Burkina Faso, 2009: case control study. Pan African Medical Journal 21:152. Crossref |
||||
| Scheelbeek PFD, Wirix AJG, Hatta M (2014). Risk factors for poor tuberculosis treatment outcomes in Makassar, Indonesia. Southeast Asian Journal of Tropical Medicine and Public Health 45:853-858 | ||||
|
Segbedji KR, Djadou KE, Tchagbele O-B (2016). Tuberculose de l'enfant au Togo: aspects épidémiologiques, diagnostiques, thérapeutiques et évolutifs. Médecine et Santé Tropicales 26:318-322. Crossref |
||||
|
Shrivastava SR, Shrivastava PS, Ramasamy J (2014) Fostering directly observed treatment in tuberculosis: a program manager's perspective. International Journal of Health Policy and Management 2:51-52. Crossref |
||||
|
Shuldiner J, Leventhal A, Chemtob D, Mor Z (2014) Mortality of tuberculosis patients during treatment in Israel, 2000-2010. International Journal of Tuberculosis and Lung Disease 18:818-823. Crossref |
||||
| Siemion-Szcześniak I, Kuś J (2009) [Treatment outcomes in culture positive pulmonary tuberculosis]. Pneumonol Alergol Pol 77:11-22 | ||||
|
Sinshaw Y, Alemu S, Fekadu A, Gizachew M (2017) Successful TB treatment outcome and its associated factors among TB/HIV co-infected patients attending Gondar University Referral Hospital, Northwest Ethiopia: an institution based cross-sectional study. BMC Infectious Diseases 17:132. Crossref |
||||
|
Sisay S, Mengistu B, Erku W, Woldeyohannes D (2016) Ten years' experience of Directly Observed Treatment Short-course (DOTS) in Gambella Regional State, Ethiopia: An evaluation of tuberculosis control program. International Journal of Mycobacteriology 5(1):S117-S118. Crossref |
||||
|
Takarinda KC, Sandy C, Masuka N (2017). Factors Associated with Mortality among Patients on TB Treatment in the Southern Region of Zimbabwe, 2013. Tuberculosis Research and Treatment 2017:6232071. Crossref |
||||
| Tchaou M, Sonhaye L, Kotosso A, Adjenou K, Agoda-Koussema L, N'TIMON B, Amadou A, Djagnikpo O (2012). Aspects radiographiques des séquelles de la tuberculose chez les personnes vivant avec le VIH/SIDA à Lomé -Togo | ||||
|
Wang X-M, Yin S-H, Du J, Du ML, Wang PY, Wu J, Horbinski CM, Wu MJ, Zheng HQ, Xu XQ, Shu W (2017). Risk factors for the treatment outcome of retreated pulmonary tuberculosis patients in China: an optimized prediction model. Epidemiology and Infection 145:1805-1814. Crossref |
||||
| World Health Organization (2018). Global tuberculosis report 2018 | ||||
|
Workicho A, Kassahun W, Alemseged F (2017). Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study. Infection and Drug Resistance 10:91-96. Crossref |
||||
|
Yee D, Valiquette C, Pelletier M (2003). Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. American Journal of Respiratory and Critical Care Medicine 167:1472-1477. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
